SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection
We investigated blood samples from fully SARS-CoV2-vaccinated subjects and from previously positive tested patients up to one year after infection with SARS-CoV2, and compared short- and long-term T cell and antibody responses, with a special focus on the recently emerged delta variant (B.1.617.2)....
Saved in:
| Published in | PloS one Vol. 17; no. 4; p. e0266701 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
25.04.2022
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | We investigated blood samples from fully SARS-CoV2-vaccinated subjects and from previously positive tested patients up to one year after infection with SARS-CoV2, and compared short- and long-term T cell and antibody responses, with a special focus on the recently emerged delta variant (B.1.617.2).
In 23 vaccinated subjects, we documented high anti-SARS-CoV2 spike protein receptor binding domain (RBD) antibody titers. Average virus neutralization by antibodies, assessed as inhibition of ACE2 binding to RBD, was 2.2-fold reduced for delta mutant vs. wild type (wt) RBD. The mean specific antibody titers were lower one year after natural infection than after vaccination; ACE2 binding to delta mutant vs. wt RBD was 1.65-fold reduced. In an additional group, omicron RBD binding was reduced compared to delta. Specific CD4+ T cell responses were measured after stimulation with peptides pools from wt, alpha, beta, gamma, or delta variant SARS-CoV2 spike proteins by flow cytometric intracellular cytokine staining. There was no significant difference in cytokine production of IFN-γ, TNF-α, or IL-2 between vaccinated subjects. T cell responses to wt or mutant SARS-CoV2 spike were significantly weaker after natural occurring infections compared to those in vaccinated individuals.
Antibody neutralisation of the delta mutant was reduced compared to wt, as assessed in a novel inhibition assay with a finger prick blood drop. Strong CD4 T cell responses were present against wt and mutant SARS-CoV2 variants, including the delta (B.1.617.2) strain, in fully vaccinated individuals, whereas they were partly weaker 1 year after natural infection. Hence, immune responses after vaccination are stronger compared to those after naturally occurring infection, pointing out the need of the vaccine to overcome the pandemic. |
|---|---|
| AbstractList | Objective We investigated blood samples from fully SARS-CoV2-vaccinated subjects and from previously positive tested patients up to one year after infection with SARS-CoV2, and compared short- and long-term T cell and antibody responses, with a special focus on the recently emerged delta variant (B.1.617.2). Methods and results In 23 vaccinated subjects, we documented high anti-SARS-CoV2 spike protein receptor binding domain (RBD) antibody titers. Average virus neutralization by antibodies, assessed as inhibition of ACE2 binding to RBD, was 2.2-fold reduced for delta mutant vs. wild type (wt) RBD. The mean specific antibody titers were lower one year after natural infection than after vaccination; ACE2 binding to delta mutant vs. wt RBD was 1.65-fold reduced. In an additional group, omicron RBD binding was reduced compared to delta. Specific CD4+ T cell responses were measured after stimulation with peptides pools from wt, alpha, beta, gamma, or delta variant SARS-CoV2 spike proteins by flow cytometric intracellular cytokine staining. There was no significant difference in cytokine production of IFN-[gamma], TNF-[alpha], or IL-2 between vaccinated subjects. T cell responses to wt or mutant SARS-CoV2 spike were significantly weaker after natural occurring infections compared to those in vaccinated individuals. Conclusion Antibody neutralisation of the delta mutant was reduced compared to wt, as assessed in a novel inhibition assay with a finger prick blood drop. Strong CD4 T cell responses were present against wt and mutant SARS-CoV2 variants, including the delta (B.1.617.2) strain, in fully vaccinated individuals, whereas they were partly weaker 1 year after natural infection. Hence, immune responses after vaccination are stronger compared to those after naturally occurring infection, pointing out the need of the vaccine to overcome the pandemic. We investigated blood samples from fully SARS-CoV2-vaccinated subjects and from previously positive tested patients up to one year after infection with SARS-CoV2, and compared short- and long-term T cell and antibody responses, with a special focus on the recently emerged delta variant (B.1.617.2). In 23 vaccinated subjects, we documented high anti-SARS-CoV2 spike protein receptor binding domain (RBD) antibody titers. Average virus neutralization by antibodies, assessed as inhibition of ACE2 binding to RBD, was 2.2-fold reduced for delta mutant vs. wild type (wt) RBD. The mean specific antibody titers were lower one year after natural infection than after vaccination; ACE2 binding to delta mutant vs. wt RBD was 1.65-fold reduced. In an additional group, omicron RBD binding was reduced compared to delta. Specific CD4+ T cell responses were measured after stimulation with peptides pools from wt, alpha, beta, gamma, or delta variant SARS-CoV2 spike proteins by flow cytometric intracellular cytokine staining. There was no significant difference in cytokine production of IFN-[gamma], TNF-[alpha], or IL-2 between vaccinated subjects. T cell responses to wt or mutant SARS-CoV2 spike were significantly weaker after natural occurring infections compared to those in vaccinated individuals. Antibody neutralisation of the delta mutant was reduced compared to wt, as assessed in a novel inhibition assay with a finger prick blood drop. Strong CD4 T cell responses were present against wt and mutant SARS-CoV2 variants, including the delta (B.1.617.2) strain, in fully vaccinated individuals, whereas they were partly weaker 1 year after natural infection. Hence, immune responses after vaccination are stronger compared to those after naturally occurring infection, pointing out the need of the vaccine to overcome the pandemic. Objective We investigated blood samples from fully SARS-CoV2-vaccinated subjects and from previously positive tested patients up to one year after infection with SARS-CoV2, and compared short- and long-term T cell and antibody responses, with a special focus on the recently emerged delta variant (B.1.617.2). Methods and results In 23 vaccinated subjects, we documented high anti-SARS-CoV2 spike protein receptor binding domain (RBD) antibody titers. Average virus neutralization by antibodies, assessed as inhibition of ACE2 binding to RBD, was 2.2-fold reduced for delta mutant vs. wild type (wt) RBD. The mean specific antibody titers were lower one year after natural infection than after vaccination; ACE2 binding to delta mutant vs. wt RBD was 1.65-fold reduced. In an additional group, omicron RBD binding was reduced compared to delta. Specific CD4+ T cell responses were measured after stimulation with peptides pools from wt, alpha, beta, gamma, or delta variant SARS-CoV2 spike proteins by flow cytometric intracellular cytokine staining. There was no significant difference in cytokine production of IFN-γ, TNF-α, or IL-2 between vaccinated subjects. T cell responses to wt or mutant SARS-CoV2 spike were significantly weaker after natural occurring infections compared to those in vaccinated individuals. Conclusion Antibody neutralisation of the delta mutant was reduced compared to wt, as assessed in a novel inhibition assay with a finger prick blood drop. Strong CD4 T cell responses were present against wt and mutant SARS-CoV2 variants, including the delta (B.1.617.2) strain, in fully vaccinated individuals, whereas they were partly weaker 1 year after natural infection. Hence, immune responses after vaccination are stronger compared to those after naturally occurring infection, pointing out the need of the vaccine to overcome the pandemic. We investigated blood samples from fully SARS-CoV2-vaccinated subjects and from previously positive tested patients up to one year after infection with SARS-CoV2, and compared short- and long-term T cell and antibody responses, with a special focus on the recently emerged delta variant (B.1.617.2). In 23 vaccinated subjects, we documented high anti-SARS-CoV2 spike protein receptor binding domain (RBD) antibody titers. Average virus neutralization by antibodies, assessed as inhibition of ACE2 binding to RBD, was 2.2-fold reduced for delta mutant vs. wild type (wt) RBD. The mean specific antibody titers were lower one year after natural infection than after vaccination; ACE2 binding to delta mutant vs. wt RBD was 1.65-fold reduced. In an additional group, omicron RBD binding was reduced compared to delta. Specific CD4+ T cell responses were measured after stimulation with peptides pools from wt, alpha, beta, gamma, or delta variant SARS-CoV2 spike proteins by flow cytometric intracellular cytokine staining. There was no significant difference in cytokine production of IFN-γ, TNF-α, or IL-2 between vaccinated subjects. T cell responses to wt or mutant SARS-CoV2 spike were significantly weaker after natural occurring infections compared to those in vaccinated individuals. Antibody neutralisation of the delta mutant was reduced compared to wt, as assessed in a novel inhibition assay with a finger prick blood drop. Strong CD4 T cell responses were present against wt and mutant SARS-CoV2 variants, including the delta (B.1.617.2) strain, in fully vaccinated individuals, whereas they were partly weaker 1 year after natural infection. Hence, immune responses after vaccination are stronger compared to those after naturally occurring infection, pointing out the need of the vaccine to overcome the pandemic. We investigated blood samples from fully SARS-CoV2-vaccinated subjects and from previously positive tested patients up to one year after infection with SARS-CoV2, and compared short- and long-term T cell and antibody responses, with a special focus on the recently emerged delta variant (B.1.617.2).OBJECTIVEWe investigated blood samples from fully SARS-CoV2-vaccinated subjects and from previously positive tested patients up to one year after infection with SARS-CoV2, and compared short- and long-term T cell and antibody responses, with a special focus on the recently emerged delta variant (B.1.617.2).In 23 vaccinated subjects, we documented high anti-SARS-CoV2 spike protein receptor binding domain (RBD) antibody titers. Average virus neutralization by antibodies, assessed as inhibition of ACE2 binding to RBD, was 2.2-fold reduced for delta mutant vs. wild type (wt) RBD. The mean specific antibody titers were lower one year after natural infection than after vaccination; ACE2 binding to delta mutant vs. wt RBD was 1.65-fold reduced. In an additional group, omicron RBD binding was reduced compared to delta. Specific CD4+ T cell responses were measured after stimulation with peptides pools from wt, alpha, beta, gamma, or delta variant SARS-CoV2 spike proteins by flow cytometric intracellular cytokine staining. There was no significant difference in cytokine production of IFN-γ, TNF-α, or IL-2 between vaccinated subjects. T cell responses to wt or mutant SARS-CoV2 spike were significantly weaker after natural occurring infections compared to those in vaccinated individuals.METHODS AND RESULTSIn 23 vaccinated subjects, we documented high anti-SARS-CoV2 spike protein receptor binding domain (RBD) antibody titers. Average virus neutralization by antibodies, assessed as inhibition of ACE2 binding to RBD, was 2.2-fold reduced for delta mutant vs. wild type (wt) RBD. The mean specific antibody titers were lower one year after natural infection than after vaccination; ACE2 binding to delta mutant vs. wt RBD was 1.65-fold reduced. In an additional group, omicron RBD binding was reduced compared to delta. Specific CD4+ T cell responses were measured after stimulation with peptides pools from wt, alpha, beta, gamma, or delta variant SARS-CoV2 spike proteins by flow cytometric intracellular cytokine staining. There was no significant difference in cytokine production of IFN-γ, TNF-α, or IL-2 between vaccinated subjects. T cell responses to wt or mutant SARS-CoV2 spike were significantly weaker after natural occurring infections compared to those in vaccinated individuals.Antibody neutralisation of the delta mutant was reduced compared to wt, as assessed in a novel inhibition assay with a finger prick blood drop. Strong CD4 T cell responses were present against wt and mutant SARS-CoV2 variants, including the delta (B.1.617.2) strain, in fully vaccinated individuals, whereas they were partly weaker 1 year after natural infection. Hence, immune responses after vaccination are stronger compared to those after naturally occurring infection, pointing out the need of the vaccine to overcome the pandemic.CONCLUSIONAntibody neutralisation of the delta mutant was reduced compared to wt, as assessed in a novel inhibition assay with a finger prick blood drop. Strong CD4 T cell responses were present against wt and mutant SARS-CoV2 variants, including the delta (B.1.617.2) strain, in fully vaccinated individuals, whereas they were partly weaker 1 year after natural infection. Hence, immune responses after vaccination are stronger compared to those after naturally occurring infection, pointing out the need of the vaccine to overcome the pandemic. Objective We investigated blood samples from fully SARS-CoV2-vaccinated subjects and from previously positive tested patients up to one year after infection with SARS-CoV2, and compared short- and long-term T cell and antibody responses, with a special focus on the recently emerged delta variant (B.1.617.2). Methods and results In 23 vaccinated subjects, we documented high anti-SARS-CoV2 spike protein receptor binding domain (RBD) antibody titers. Average virus neutralization by antibodies, assessed as inhibition of ACE2 binding to RBD, was 2.2-fold reduced for delta mutant vs. wild type (wt) RBD. The mean specific antibody titers were lower one year after natural infection than after vaccination; ACE2 binding to delta mutant vs. wt RBD was 1.65-fold reduced. In an additional group, omicron RBD binding was reduced compared to delta. Specific CD4+ T cell responses were measured after stimulation with peptides pools from wt, alpha, beta, gamma, or delta variant SARS-CoV2 spike proteins by flow cytometric intracellular cytokine staining. There was no significant difference in cytokine production of IFN-γ, TNF-α, or IL-2 between vaccinated subjects. T cell responses to wt or mutant SARS-CoV2 spike were significantly weaker after natural occurring infections compared to those in vaccinated individuals. Conclusion Antibody neutralisation of the delta mutant was reduced compared to wt, as assessed in a novel inhibition assay with a finger prick blood drop. Strong CD4 T cell responses were present against wt and mutant SARS-CoV2 variants, including the delta (B.1.617.2) strain, in fully vaccinated individuals, whereas they were partly weaker 1 year after natural infection. Hence, immune responses after vaccination are stronger compared to those after naturally occurring infection, pointing out the need of the vaccine to overcome the pandemic. |
| Audience | Academic |
| Author | Richardson, Jennifer R. Holthoff, Hans-Peter Ungerer, Martin Götz, Ralph Lohse, Martin J. Mayr, Vanessa |
| AuthorAffiliation | ISAR Bioscience, Planegg, Germany Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, UNITED STATES |
| AuthorAffiliation_xml | – name: ISAR Bioscience, Planegg, Germany – name: Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, UNITED STATES |
| Author_xml | – sequence: 1 givenname: Jennifer R. surname: Richardson fullname: Richardson, Jennifer R. – sequence: 2 givenname: Ralph surname: Götz fullname: Götz, Ralph – sequence: 3 givenname: Vanessa surname: Mayr fullname: Mayr, Vanessa – sequence: 4 givenname: Martin J. surname: Lohse fullname: Lohse, Martin J. – sequence: 5 givenname: Hans-Peter surname: Holthoff fullname: Holthoff, Hans-Peter – sequence: 6 givenname: Martin orcidid: 0000-0002-5198-3399 surname: Ungerer fullname: Ungerer, Martin |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35468147$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk11r2zAUhs3oWD-2fzA2wWBsF8kk2ZLtXQxC2EegUGi63gpFlhIFW3IluVtv9tsnJ26JSxnDFzLnPOeVzss5p8mRsUYmyWsEpyjN0aet7Zzh9bSN4SnElOYQPUtOUJniCcUwPTr4P05Ovd9CSNKC0hfJcUoyWqAsP0n-LGeXy8ncXmPwS9cVCHetBNxUoOkCNwH4VgqttACbrrGO17vcFRCyroFums7ocAe0B75rpdPWAa6CdOCWC6END9oaEDbcDOEY6XoRbZQUffJl8lzx2stXw3mW_Pz29Wr-Y3J-8X0xn51PBC1xmOC0il1UosAVFFBJhHKRIlTwXBapwlySFZRixZUqEValKjjKRIkiu8KZKkV6lrzd67a19WywzjNMCYF5RmgZicWeqCzfstbphrs7Zrlmu4B1a8Zd0KKWLKOI56QQeZXxDNGSY0xXq0xhiMuUKBi1vgy3datGVkKaELseiY4zRm_Y2t6yEqZ5fHYU-DAIOHvTSR9Yo33vOTfSdvt3E4pgSSL67hH6dHcDteaxgWi_jfeKXpTN4tyQjMQBitT0CSp-lWy0iHOmdIyPCj6OCiIT5O-w5p33bLG8_H_24nrMvj9gN5LXYeNt3fUj48fgm0OnHyy-H_AIZHtAOOu9k-oBQZD1e3RvF-v3iA17FMs-PyoTOuzGOTqi638X_wVMpiPH |
| CitedBy_id | crossref_primary_10_3390_microorganisms11040940 crossref_primary_10_3390_vaccines10071142 crossref_primary_10_1007_s00216_022_04416_6 crossref_primary_10_1016_j_carbpol_2024_121884 crossref_primary_10_1146_annurev_immunol_101721_061120 crossref_primary_10_3390_v14071447 crossref_primary_10_1038_s42003_024_07048_x crossref_primary_10_57187_s_3732 crossref_primary_10_1186_s12879_024_09644_y crossref_primary_10_3390_biomedicines10071526 crossref_primary_10_1007_s00005_023_00673_0 crossref_primary_10_1371_journal_pone_0288713 crossref_primary_10_3389_fimmu_2024_1353353 |
| Cites_doi | 10.1126/scitranslmed.abf7517 10.1016/S0140-6736(20)30251-8 10.1056/NEJMoa2106599 10.1016/j.cell.2020.02.052 10.1016/j.cell.2020.11.020 10.1038/s41590-020-00808-x 10.1038/s41423-020-00573-9 10.1016/j.cell.2020.11.029 10.1038/s41467-021-21856-3 10.1056/NEJMoa2034577 10.1038/s41598-019-38885-0 10.1016/j.cell.2020.05.015 10.1056/NEJMoa2108891 10.1016/j.cell.2020.02.058 10.1038/nm.3350 10.1038/nm.2612 10.1126/science.abd3871 10.1038/s41586-021-03696-9 10.1016/S0140-6736(20)32661-1 10.1038/s41586-020-2179-y 10.1038/s41586-020-2798-3 10.1056/NEJMoa2035389 10.1038/s41586-021-03693-y |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2022 Public Library of Science 2022 Richardson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 Richardson et al 2022 Richardson et al |
| Copyright_xml | – notice: COPYRIGHT 2022 Public Library of Science – notice: 2022 Richardson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 Richardson et al 2022 Richardson et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU COVID D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0266701 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central (New) Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Coronavirus Research Database ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium ProQuest advanced technologies & aerospace journals ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection Coronavirus Research Database ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Agricultural Science Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | SARS-CoV2-specific T cells |
| EISSN | 1932-6203 |
| ExternalDocumentID | 2655074569 oai_doaj_org_article_461a758c7d4a4169a226bb4f202935f0 PMC9037910 A701545266 35468147 10_1371_journal_pone_0266701 |
| Genre | Journal Article |
| GeographicLocations | Germany |
| GeographicLocations_xml | – name: Germany |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM 3V. ADRAZ BBORY CGR CUY CVF ECM EIF IPNFZ NPM RIG PMFND 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K COVID DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS RC3 7X8 5PM PUEGO AAPBV ABPTK BBAFP N95 |
| ID | FETCH-LOGICAL-c692t-23d203dc82d0c0fe117c3118a7e83f2ae5b0ecbaff912f9f8a14c910c0b24f9c3 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Sun Jan 01 07:45:43 EST 2023 Wed Aug 27 01:26:43 EDT 2025 Thu Aug 21 13:44:19 EDT 2025 Fri Jul 11 09:24:55 EDT 2025 Fri Jul 25 10:04:10 EDT 2025 Tue Jun 17 21:08:14 EDT 2025 Tue Jun 10 20:34:24 EDT 2025 Fri Jun 27 03:37:24 EDT 2025 Fri Jun 27 05:03:48 EDT 2025 Thu May 22 21:24:16 EDT 2025 Wed Feb 19 02:26:06 EST 2025 Tue Jul 01 02:49:54 EDT 2025 Thu Apr 24 22:55:17 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c692t-23d203dc82d0c0fe117c3118a7e83f2ae5b0ecbaff912f9f8a14c910c0b24f9c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: The fact that all authors are employees of the non-profit ISAR Bioscience Institute which formally acts as a biotech company does not alter our adherence to PLOS ONE policies on sharing data and materials. The authors or ISAR do not impose any restrictions on sharing of data and/or materials. HPH and MU shared senior authorship on this work. |
| ORCID | 0000-0002-5198-3399 |
| OpenAccessLink | https://doaj.org/article/461a758c7d4a4169a226bb4f202935f0 |
| PMID | 35468147 |
| PQID | 2655074569 |
| PQPubID | 1436336 |
| PageCount | e0266701 |
| ParticipantIDs | plos_journals_2655074569 doaj_primary_oai_doaj_org_article_461a758c7d4a4169a226bb4f202935f0 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9037910 proquest_miscellaneous_2655561095 proquest_journals_2655074569 gale_infotracmisc_A701545266 gale_infotracacademiconefile_A701545266 gale_incontextgauss_ISR_A701545266 gale_incontextgauss_IOV_A701545266 gale_healthsolutions_A701545266 pubmed_primary_35468147 crossref_primary_10_1371_journal_pone_0266701 crossref_citationtrail_10_1371_journal_pone_0266701 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20220425 |
| PublicationDateYYYYMMDD | 2022-04-25 |
| PublicationDate_xml | – month: 4 year: 2022 text: 20220425 day: 25 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2022 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | F. Krammer (pone.0266701.ref001) 2020; 586 SF Lumley (pone.0266701.ref027) 2020 LR Baden (pone.0266701.ref003) 2020; 384 AC Walls (pone.0266701.ref007) 2020; 181 S Sridhar (pone.0266701.ref025) 2013; 19 QX Long (pone.0266701.ref005) 2020; 395 JL Bernal (pone.0266701.ref031) 2021; 385 FP Polack (pone.0266701.ref002) 2020; 383 JM Carreño (pone.0266701.ref019) B Bosnjak (pone.0266701.ref011) 2021; 18 S Kim (pone.0266701.ref021) KE Gooch (pone.0266701.ref024) 2019; 9 DH Jo (pone.0266701.ref032) 2021; 9 A Choi (pone.0266701.ref017) J Mateus (pone.0266701.ref012) 2020; 370 M Hoffmann (pone.0266701.ref008) 2020; 181 M Voysey (pone.0266701.ref004) 2020; 397 A Ogbe (pone.0266701.ref014) 2021; 12 T Pilishvili (pone.0266701.ref030) 2021; 385 A Nelde (pone.0266701.ref029) 2021; 22 LB Rodda (pone.0266701.ref013) 2021; 184 D Planas (pone.0266701.ref020) 2021 TM Wilkinson (pone.0266701.ref026) 2012; 18 C Kreer (pone.0266701.ref010) 2020; 182 Z Wang (pone.0266701.ref015) 2021; 595 DT Skelly (pone.0266701.ref022) 2021 E Volz (pone.0266701.ref006) 2021; 184 J Shang (pone.0266701.ref009) 2020; 581 T Bilich (pone.0266701.ref016) 2021; 13 A Grifoni (pone.0266701.ref028) 2020; 181 J Liu (pone.0266701.ref018) 2021; 596 RP Payne (pone.0266701.ref023) 2021 |
| References_xml | – volume: 13 start-page: eabf7517 issue: 590 year: 2021 ident: pone.0266701.ref016 article-title: T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals publication-title: Sci Transl Med doi: 10.1126/scitranslmed.abf7517 – volume: 395 start-page: 565 year: 2020 ident: pone.0266701.ref005 article-title: Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding publication-title: Lancet doi: 10.1016/S0140-6736(20)30251-8 – ident: pone.0266701.ref019 article-title: Reduced neutralizing activity of post-SARS-1 CoV-2 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37 publication-title: medRxiv – volume: 385 start-page: e90 issue: 25 year: 2021 ident: pone.0266701.ref030 article-title: Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel publication-title: N Engl J Med doi: 10.1056/NEJMoa2106599 – volume: 181 start-page: 271 year: 2020 ident: pone.0266701.ref008 article-title: SARS CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor publication-title: Cell doi: 10.1016/j.cell.2020.02.052 – year: 2021 ident: pone.0266701.ref020 article-title: Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization publication-title: Nature – volume: 184 start-page: 64 year: 2021 ident: pone.0266701.ref006 article-title: Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity publication-title: Cell doi: 10.1016/j.cell.2020.11.020 – volume: 22 start-page: 74 year: 2021 ident: pone.0266701.ref029 article-title: SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition publication-title: Nature Immunology doi: 10.1038/s41590-020-00808-x – volume: 18 start-page: 936 year: 2021 ident: pone.0266701.ref011 article-title: Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods publication-title: Cell Mol Immunol doi: 10.1038/s41423-020-00573-9 – volume: 184 start-page: 169 year: 2021 ident: pone.0266701.ref013 article-title: Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19 publication-title: Cell doi: 10.1016/j.cell.2020.11.029 – volume: 12 start-page: 2055 year: 2021 ident: pone.0266701.ref014 article-title: T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses publication-title: Nat Commun doi: 10.1038/s41467-021-21856-3 – year: 2020 ident: pone.0266701.ref027 article-title: Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers publication-title: N Engl J Med – volume: 383 start-page: 2603 year: 2020 ident: pone.0266701.ref002 article-title: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2034577 – volume: 9 start-page: 1 year: 2019 ident: pone.0266701.ref024 article-title: Heterosubtypic cross-protection correlates with cross-reactive interferon-gamma secreting lymphocytes in the ferret model of influenza publication-title: Sci. Rep doi: 10.1038/s41598-019-38885-0 – year: 2021 ident: pone.0266701.ref023 article-title: Sustained T cell immunity, protection and boosting using extended dosing intervals of BNT162b2 mRNA vaccine publication-title: Pre-publication – volume: 181 start-page: 1489 year: 2020 ident: pone.0266701.ref028 article-title: Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals publication-title: Cell doi: 10.1016/j.cell.2020.05.015 – year: 2021 ident: pone.0266701.ref022 article-title: Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS CoV-2 variants of concern publication-title: Research Square – volume: 385 start-page: 585 year: 2021 ident: pone.0266701.ref031 article-title: Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant publication-title: N Engl J Med doi: 10.1056/NEJMoa2108891 – volume: 181 start-page: 281 year: 2020 ident: pone.0266701.ref007 article-title: Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein publication-title: Cell doi: 10.1016/j.cell.2020.02.058 – volume: 19 start-page: 1305 year: 2013 ident: pone.0266701.ref025 article-title: Cellular immune correlates of protection against symptomatic pandemic influenza publication-title: Nature Med doi: 10.1038/nm.3350 – volume: 18 start-page: 274 year: 2012 ident: pone.0266701.ref026 article-title: Preexisting influenza-specific CD4 + T cells correlate with disease protection against influenza challenge in humans publication-title: Nat Med doi: 10.1038/nm.2612 – volume: 370 start-page: 89 issue: 6512 year: 2020 ident: pone.0266701.ref012 article-title: Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans publication-title: Science doi: 10.1126/science.abd3871 – volume: 595 start-page: 426 issue: 7867 year: 2021 ident: pone.0266701.ref015 article-title: Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection publication-title: Nature doi: 10.1038/s41586-021-03696-9 – volume: 9 start-page: 1145 issue: 10 year: 2021 ident: pone.0266701.ref032 article-title: Rapidly declining SARS-CoV-2 antibody titers within 4 months after BNT162b2 vaccination publication-title: Vaccines (Basel), v.9(10) – ident: pone.0266701.ref021 article-title: Differential Interactions Between Human ACE2 and Spike RBD of SARSCoV-2 Variants of Concern publication-title: bioRxiv – volume: 397 start-page: 99 year: 2020 ident: pone.0266701.ref004 article-title: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK publication-title: Lancet doi: 10.1016/S0140-6736(20)32661-1 – volume: 581 start-page: 221 year: 2020 ident: pone.0266701.ref009 article-title: Structural basis of receptor recognition by SARS-CoV-2 publication-title: Nature doi: 10.1038/s41586-020-2179-y – volume: 182 start-page: 843 year: 2020 ident: pone.0266701.ref010 article-title: Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 publication-title: Patients. Cell – volume: 586 start-page: 516 year: 2020 ident: pone.0266701.ref001 article-title: SARS-CoV-2 vaccines in development publication-title: Nature doi: 10.1038/s41586-020-2798-3 – volume: 384 start-page: 403 year: 2020 ident: pone.0266701.ref003 article-title: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2035389 – ident: pone.0266701.ref017 article-title: Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants publication-title: BioRxive – volume: 596 start-page: 273 issue: 7871 year: 2021 ident: pone.0266701.ref018 article-title: BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants publication-title: Nature doi: 10.1038/s41586-021-03693-y |
| SSID | ssj0053866 |
| Score | 2.4630702 |
| Snippet | We investigated blood samples from fully SARS-CoV2-vaccinated subjects and from previously positive tested patients up to one year after infection with... Objective We investigated blood samples from fully SARS-CoV2-vaccinated subjects and from previously positive tested patients up to one year after infection... Objective We investigated blood samples from fully SARS-CoV2-vaccinated subjects and from previously positive tested patients up to one year after infection... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0266701 |
| SubjectTerms | ACE2 Angiotensin-Converting Enzyme 2 Antibodies Authorship Binding Biology and Life Sciences Blood CD4 antigen Complications and side effects COVID-19 - prevention & control Cytokines Experiments Flow cytometry Health aspects Humans Humoral immunity Immune response Infections Interleukin 2 Kinases Lymphocytes Lymphocytes T Medicine and Health Sciences Mutants Mutation Neutralization Pandemics Patient outcomes Peptides Proteins Research and Analysis Methods RNA, Viral SARS-CoV-2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Spike Glycoprotein, Coronavirus - genetics Spike protein T cells T-Lymphocytes Tumor necrosis factor-α Vaccination Vaccines Viral diseases Viral Envelope Proteins Viral Vaccines Viruses γ-Interferon |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQnrggyqsLBQxCAg5pE9uJk-NSURUkQOq2VW-RX2lXapNVs0Hiwm9nxnGiBlUqB67xJNqdGU--cWa-IeSdiI1QSe4iLqSLRG4tbKlURcxYkWvnIHDiOeS379nhifh6lp7dGPWFNWE9PXCvuD2RJQowrZFWKAAPhQK8oLWoIGkveFr5bB3eeUMy1cdg2MVZFhrluEz2gl12103tdiHryGQYAjO8iDxf_xiVZ-vLpr0Ncv5dOXnjVXTwkDwIGJIu-t--Re65-hHZCru0pR8ClfTHx-T3cnG0jPabU0YBE1uKB65U1ZZedTg9mGKfJdYK0YvuClv1_doxxdN8uvKdI5tfdNXStkNC5Oaa-pHi9KcyZtUfI1I8eg-XPUkoPGQo8KqfkJODz8f7h1GYuBCZrGCbiHHLYm5Nzmxs4soliTQcUhAlXc4rplyqY2e0qqoiYVVR5SoRBgCHiTUTVWH4UzKrQcfbhGoNwSSPq9wAgtCxwc-HqbZWpSlPheVzwgf1lybQkeNUjMvSf2OTkJb02izRaGUw2pxE413rno7jDvlPaNlRFsm0_QVwsTK4WHmXi83Ja_SLsu9MHUNCuZBhRHs2J2-9BBJq1Fixc666ti2__Dj9B6Hl0UTofRCqGlCHUaFLAv4TEnVNJHcmkhAWzGR5G7140Epbsgyp6wAvF3Dn4Nm3L78Zl_GhWIVXu6brZRBvF-mcPOs3wqhZMGqWJ0LOiZxskYnqpyv16sLzmRcxl-BEz_-HrV6Q-wwbVGIRsXSHzDbXnXsJsHGjX_kI8Qcax2ru priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9QwDI_geOEFMb7WMSAgJOChW5qmTfuEjolpIAHSbpvurUrzsZ20tcf1DokX_nbsNi0UTcBr7VZ3duw4jv0zIS8F00JFmQ1jIW0oMmPApBIVcm1EVloLjhPzkJ8-p0en4uM8mfuEW-PLKnuf2DpqU2vMke_zFJG3YLvP3y6_hjg1Cm9X_QiNm-QWQpdhSZecDwcusOU09e1ysYz2vXb2lnVl9-DskUo_CqbfjlrU_sE3T5aXdXNd4Pln_eRvG9LhXXLHR5J02ql-i9yw1T2y5W21oa89oPSb--THbHo8Cw_qM04hMjYU065UVYZebXCGMMVuS6wYohebK2zYb2knFHP6dNH2j6y_00VDmw3CItcr2g4Wp9-U1osumUgxAe8ft1Ch8JG-zKt6QE4P358cHIV-7kKo05yvQx4bzmKjM26YZs5GkdQxHESUtFnsuLJJyawulXN5xF3uMhUJDWGHZiUXLtfxQzKpQMbbhJYluJSMuUxDHFEyjZeISWmMSpI4ESYOSNyLv9AelBxnY1wW7U2bhMNJJ80ClVZ4pQUkHN5adqAc_-B_h5odeBFSu31Qr84Lb6GFSCMFhyctjVAQpeYKAtOyFI4ziIgSxwLyDNdF0fWnDo6hmEo_qD0NyIuWA2E1KqzbOVebpik-fDn7D6bZ8YjplWdyNYhDK98rAf8J4bpGnLsjTnAOekTexlXcS6UpfpkRvNmv7OvJzwcyfhRr8SpbbzoejLrzJCCPOkMYJAtKTbNIyIDIkYmMRD-mVIuLFtU8Z7GERbTz95_1mNzm2IDCRMiTXTJZrzb2CYSF6_Jpa_s_AQ3lY5U priority: 102 providerName: ProQuest |
| Title | SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35468147 https://www.proquest.com/docview/2655074569 https://www.proquest.com/docview/2655561095 https://pubmed.ncbi.nlm.nih.gov/PMC9037910 https://doaj.org/article/461a758c7d4a4169a226bb4f202935f0 http://dx.doi.org/10.1371/journal.pone.0266701 |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3Nb9MwFLdGd-GCGF8LjGIQEnBIlThOnBwQ6qqWgbSB2nXqLXKcZKvUJaVpEbvsb-c9x40IKh8XH-JnS3n2e_75-X0Q8po7iks3zGyPi8zmYZqCSPnSZirlYZJloDjRDnl6FpxM-eeZP9sj25qthoHVzqsd1pOarha9H99uPoDAv9dVG4S7HdRblkXWgztFIDCgax_OJoGiesqbdwWQbv16iajFDpjjmWC6P83SOqx0Tv9Gc3eWi7LaBUt_96785bga3Sf3DM6k_XpjHJC9rHhADowkV_StSTf97iG5nfTHE3tQXjAKuDmlaJSlskjp9QYrDFOMxUR_Inq1ucZwft13TtHiT-c6umR9Q-cVrTaYNLlcUV12nH6XSs1rUyNF87z5rBOJwiRbJ7DiEZmOhueDE9tUZbBVELG1zbwUGJeqkKWOcvLMdYXy4JoiRRZ6OZOZnziZSmSeRy7LozyULlcASpSTMJ5HyntMOgXw-JDQJAGFEzp5qABlJI7CJ0Y_SVPp-57PU88i3pb9sTIpy7FyxiLW73ACri41N2NctNgsmkXsZtSyTtnxD_pjXNmGFhNu6w_l6jI28hvzwJVwtVIi5RIwbCQBtiYJz5kDeMnPHYu8wH0R19GrjdqI-8KUcQ8s8kpTYNKNAr16LuWmquJPXy7-g2gybhG9MUR5CexQ0kRSwD9hMq8W5VGLElSHanUf4i7ecqWKWYDp7QBTRzByu7N3d79sunFS9NQrsnJT0yAmj3yLPKkFoeEsLGoQulxYRLREpMX6dk8xv9I5zyPHE7CJnv79h56RuwzDUxxuM_-IdNarTfYcQOM66ZI7YiagDQcutqOPXbJ_PDz7Ou5qM0xX6wlsb4c_AR8rcTk |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKcoALory6UKhBIOCQ1nGc1wGhpVDt0gdSX9pbcGynXalNls0uqBd-Er-RmcQJBFXApdd4YiUz45mxPfMNIc8FU0K6kXE8ERpHRFrDkvKlw5UWUWoMGE48h9zdC4ZH4uPYHy-RH00tDKZVNjaxMtS6UHhGvsEDRN4Cdx-_nX5xsGsU3q42LTRqtdg2F99gy1a-Gb0H-b7gfOvD4ebQsV0FHBXEfO5wT3PmaRVxzRTLjOuGyoMwW4Ym8jIujZ8yo1KZZbHLsziLpCsUOFXFUi6yWHkw7zVyHRwvwxUVjtsNHtiOILDleV7oblhtWJ8WuVmHvU4Q2tYzjfurugS0vqA3PSvKywLdP_M1f3OAW7fJLRu50kGtastkyeR3yLK1DSV9ZQGsX98l3w8G-wfOZnHMKUTimuIxL5W5pucL7FlMsboTM5To6eIcAQKqsUOKdwh0UtWrzC_opKTlAmGYixmtGpnTr1KpSX14SfHA3z6uoElhkiatLL9Hjq5EIvdJLwcerxCapmDCIpZFCuKWlCm8tPRTraXve77QXp94DfsTZUHQsRfHWVLd7IWwGaq5maDQEiu0PnHat6Y1CMg_6N-hZFtahPCuHhSzk8RahEQEroTNmgq1kBAVxxIC4TQVGWcQgfkZ65M11IukrodtDVEyCG1j-KBPnlUUCOORY57QiVyUZTL6dPwfRAf7HaKXligrgB1K2toM-CeEB-tQrnYowRipzvAKanHDlTL5tWzhzUazLx9-2g7jpJj7l5tiUdNglB_7ffKgXggtZ0GoQeSKsE_CzhLpsL47kk9OKxT1mHkhKNHDv3_WGrkxPNzdSXZGe9uPyE2OxS9MONxfJb35bGEeQ0g6T59UdoCSz1dteH4CE5ehgg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkRAXRHk1UKhBIOCQNnGcODkgVFpWXQoFdduqt-DYTrtSmyybXVAv_DB-HTOJEwiqgEuv8cRK5vF5bM-DkKfcU1z6sXEDLozLY63BpELpMqV5nBkDwInnkB92o-0D_u4oPFogP9pcGAyrbDGxBmpdKjwjX2cRVt6C5T5Zz21YxKetwevJFxc7SOFNa9tOo1GRHXP-DbZv1avhFsj6GWODt_ub267tMOCqKGEzlwWaeYFWMdOe8nLj-0IF4HJLYeIgZ9KEmWdUJvM88Vme5LH0uYIFVnkZ43miApj3CrkqgtBHGxNH3WYPcCSKbKpeIPx1qxlrk7Iwa7DviYRtQ9MuhXXHgG5dWJycltVFTu-fsZu_LYaDm-SG9WLpRqN2S2TBFLfIksWJir6wxaxf3ibfRxt7I3ezPGQUvHJN8ciXykLTszn2L6aY6YnRSvRkfobFAuqxfYr3CXRc567Mzum4otUcSzKXU1o3NadfpVLj5iCT4uG_fVyXKYVJ2hCz4g45uBSJ3CWLBfB4mdAsAziLvTxW4MNknsILzDDTWoZhEHIdOCRo2Z8qWxAd-3KcpvUtn4CNUcPNFIWWWqE5xO3emjQFQf5B_wYl29FiOe_6QTk9Ti06pDzyJWzclNBcgoecSHCKs4znzANvLMw9h6yiXqRNbmwHSumGsE3iI4c8qSmwpEeBxnEs51WVDj8e_gfRaK9H9NwS5SWwQ0mbpwH_hKXCepQrPUoAJtUbXkYtbrlSpb9MGN5sNfvi4cfdME6KcYCFKecNDXr8SeiQe40hdJwFoUaxz4VDRM9EeqzvjxTjk7qieuIFApTo_t8_a5VcA8hJ3w93dx6Q6wzzYDzusnCFLM6mc_MQvNNZ9qiGAUo-Xzbu_ASTeaW4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SARS-CoV2+wild+type+and+mutant+specific+humoral+and+T+cell+immunity+is+superior+after+vaccination+than+after+natural+infection&rft.jtitle=PloS+one&rft.au=Richardson%2C+Jennifer+R&rft.au=G%C3%B6tz%2C+Ralph&rft.au=Mayr%2C+Vanessa&rft.au=Lohse%2C+Martin+J&rft.date=2022-04-25&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=17&rft.issue=4&rft.spage=e0266701&rft_id=info:doi/10.1371%2Fjournal.pone.0266701&rft.externalDocID=A701545266 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |